SPOTLIGHT: FDA tightens access to acne drug

Federal regulators are establishing a national registry for the thousands of Americans who take the acne drug Accutane and people who prescribe and dispense it. The registry is part of a major initiative to tighten access to the medicine, which causes birth defects. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.